ストックスクリーナーアプリを入手
41.72
0.65%
0.2432
前日終値:
$41.48
開ける：
$41.39
24時間の取引高:
2.90M
Relative Volume:
0.45
時価総額：
$30.15B
収益：
$8.26M
当期純損益:
$-397.91M
株価収益率:
-82.85
EPS:
-0.5036
ネットキャッシュフロー:
$-758.56M
1週間 パフォーマンス:
+22.15%
1か月 パフォーマンス:
+14.89%
6か月 パフォーマンス:
+41.38%
1年 パフォーマンス:
+209.72%
1日の値動き範囲:
$41.08
$41.98
1週間の範囲:
$33.67
$42.50
52週間の値動き範囲:
$13.39
$42.50
Roivant Sciences Ltd Stock (ROIV) Company Profile
Compare ROIV vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
41.73 | 29.96B | 8.26M | -397.91M | -758.56M | -0.5036 |
VRTX
Vertex Pharmaceuticals Inc
|
520.89 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
802.22 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,003.96 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.05 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.63 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-20 | 開始されました | Bernstein | Outperform |
| 2025-09-02 | 開始されました | Citigroup | Buy |
| 2025-07-10 | 再開されました | Goldman | Buy |
| 2024-02-15 | 開始されました | Wolfe Research | Outperform |
| 2024-01-05 | 開始されました | Piper Sandler | Overweight |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-10-17 | 開始されました | Guggenheim | Buy |
| 2023-06-08 | 開始されました | BofA Securities | Neutral |
| 2022-10-27 | 開始されました | JP Morgan | Overweight |
| 2022-05-23 | 開始されました | SVB Leerink | Outperform |
| 2022-04-29 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-12-15 | 開始されました | Goldman | Buy |
| 2021-11-08 | 開始されました | H.C. Wainwright | Buy |
| 2021-10-28 | 開始されました | Citigroup | Buy |
| 2021-10-26 | 開始されました | Cowen | Outperform |
| 2021-10-26 | 開始されました | Jefferies | Buy |
| 2021-10-26 | 開始されました | Truist | Buy |
すべてを表示
Roivant Sciences Ltd (ROIV) 最新ニュース
H.C. Wainwright raises Roivant Sciences price target on trial data - Investing.com
TD Cowen raises Roivant Sciences stock price target on trial data - Investing.com
Why Did DELL, ROIV, SHEL Stocks Surge To 52-Week Highs Today? - Yahoo Finance
Roivant (ROIV) Soars to All-Time High; Q2 Hedge Fund Holdings Surge 41% - Yahoo Finance
TD Cowen Maintains Roivant Sciences(ROIV.US) With Buy Rating, Raises Target Price to $55 - Moomoo
Why is Roivant Sciences stock surging today? By Investing.com - Investing.com Australia
Biotech Trial Wins Sent Roivant And Pharvaris Higher - Finimize
ROIV Looks 472.1% Overvalued on GF Value™ Amid Clinical Trial Su - GuruFocus
Roivant Sciences soars 19% on positive mosliciguat trial results (ROIV:NASDAQ) - Seeking Alpha
Roivant Sciences (NASDAQ: ROIV) director moves to sell shares after option exercise - Stock Titan
ROIV Maintained by HC Wainwright & Co. -- Price Target Raised to $47 - GuruFocus
These 2 Biotech Stocks Hit Record Highs Today – What’s Driving The Rallies? - Yahoo Finance
Roivant shares jump 17% as lung disease drug meets trial goals - Investing.com Canada
Roivant Sciences Surges 17.7% Amid Sector-Wide Rally - AlphaStreet
Jefferies raises Roivant Sciences stock price target on trial data By Investing.com - Investing.com South Africa
Roivant Sciences Stock Soars as Experimental Inhaled Drug Hits Mid-Stage Trial Goals - Barron's
ROIV Stock Jumps As FDA Clears LISRAYA And Analysts Hike Targets - StocksToTrade
ROIV Stock Jumps As LISRAYA FDA Approval Ignites Momentum - timothysykes.com
Roivant at Wells Fargo conference: pipeline momentum lifts outlook By Investing.com - Investing.com Canada
Transcript : Roivant Sciences Ltd. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-08-2026 10:15 AM - marketscreener.com
Crude Oil Gains 1.5%; ABM Posts Upbeat Q3 Earnings - Benzinga
Jefferies Maintains Roivant Sciences(ROIV.US) With Buy Rating, Raises Target Price to $52 - Moomoo
Roivant Shares Surge as Mosliciguat Hits Primary Endpoint in Phase 2 PH-ILD Study - Minichart
Roivant's experimental lung disease drug meets goals in mid-stage study - Reuters
Roivant Sciences Rallies as Mosliciguat Phase 2 Data Beat Key Endpoints - Quiver Quantitative
Roivant surges on ‘exceptional’ results; Bristol Myers touts first-of-its-kind CAR-T therapy - Yahoo Finance
Roivant’s pulmonary hypertension drug shines with ‘blowout’ Phase 2 data - BioSpace
Roivant Sciences stock surges on positive PH-ILD trial data - Investing.com
Roivant Sciences, Pharvaris, IonQ And Other Big Stocks Moving Higher On Tuesday - Benzinga
Roivant Sciences stock hits all-time high at 39.99 USD By Investing.com - Investing.com Canada
Roivant Sciences stock hits all-time high at 39.99 USD - Investing.com
ROIV: Mosliciguat delivered unprecedented PVR reduction and functional gains in PH-ILD, with strong safety - TradingView
Up to 200,000 PH-ILD patients lack options as Roivant (NASDAQ: ROIV) moves mosliciguat into a Phase 3 trial - Stock Titan
Roivant Stock Surges on 'Robust' Data from Rare Lung Disease Candidate - Yahoo Finance
ROIV Looks 381.9% Overvalued on GF Value™ - GuruFocus
Dr. Gillian Cannon Joins Lindus Therapeutics’ Board as a Non-Executive Director - GlobeNewswire Inc.
Roivant reports mosliciguat Phase 2 PH-ILD results - grafa.com
Roivant’s Experimental Lung Disease Drug Hits Key Phase 2 Goal – ROIV Stock Tracks All-Time High - Yahoo Finance
Why Is ROIV Stock Tracking Record Highs In Pre-Market Today? - Stocktwits
S&P 500 Futures Decline in Premarket Trading; Roivant Sciences, Bloom Energy Lead - Barron's
Roivant stock climbs on mid-stage trial win (ROIV:NASDAQ) - Seeking Alpha
Roivant Sciences Shares Rise After Phase 2 Mosliciguat Results - Yahoo Finance
Roivant reports positive phase 2 trial results for mosliciguat By Investing.com - Investing.com Nigeria
Why is Roivant Sciences stock surging today? - Investing.com
Roivant’s Mosliciguat Heads To Phase III After 56% PVR Reduction In PH-ILD - insights.citeline.com
Up to 200,000 people live with this lung disease. Roivant starts a new trial. - Stock Titan
What Lisraya’s $35,000 Monthly Price Could Mean for Roivant (ROIV) - Yahoo! Finance Canada
Roivant Wins Approval for the First Oral Dermatomyositis Drug. How Large is the Opportunity? - Yahoo! Finance Canada
Roivant Sciences Ltd. (ROIV) Stock Analysis: Exploring A 20% Upside In The Biotech Sphere - DirectorsTalk Interviews
Roivant to present phase 2 pulmonary hypertension study results By Investing.com - Investing.com Australia
ROIV Stock Nears Record High –Retail Traders See Breakout After Surprise Earnings Beat - Stocktwits
Roivant Sciences Ltd (ROIV) 財務データ
収益
当期純利益
現金流量
EPS
Roivant Sciences Ltd (ROIV) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Venker Eric | President & Immunovant CEO |
Aug 28 '26 |
Option Exercise |
3.85 |
200,000 |
770,000 |
1,799,154 |
| Venker Eric | President & Immunovant CEO |
Aug 28 '26 |
Sale |
35.77 |
200,000 |
7,153,393 |
1,599,154 |
2.76%
0.71%
大文字化:
|
ボリューム (24 時間):